Cargando…
Vulvar malignancies: an interdisciplinary perspective
Vulvar cancer represents the fourth most common gynecologic malignancy and is often encountered by the general Dermatologist or Gynecologist. Dermatooncologists and Gynecologic Oncologists share expertise in this field and the diagnosis and treatment should ideally be interdisciplinary. All subtypes...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972795/ https://www.ncbi.nlm.nih.gov/pubmed/31829526 http://dx.doi.org/10.1111/ddg.13995 |
_version_ | 1783489908440039424 |
---|---|
author | Wohlmuth, Christoph Wohlmuth‐Wieser, Iris |
author_facet | Wohlmuth, Christoph Wohlmuth‐Wieser, Iris |
author_sort | Wohlmuth, Christoph |
collection | PubMed |
description | Vulvar cancer represents the fourth most common gynecologic malignancy and is often encountered by the general Dermatologist or Gynecologist. Dermatooncologists and Gynecologic Oncologists share expertise in this field and the diagnosis and treatment should ideally be interdisciplinary. All subtypes are typically seen in the later decades of life, although all histologic subtypes have been described in women younger than 30 years. The diagnosis is often delayed. Exact mapping of biopsies is of high importance, as the location and distance from the midline guides the surgical approach depending on the underlying histology. Squamous cell carcinoma accounts for more than 76 % of vulvar cancer with vulvar intraepithelial neoplasia being an important precursor. Basal cell carcinoma is the second most common vulvar malignancy. Melanoma accounts for 5.7 % of vulvar cancer and has a worse prognosis compared to cutaneous melanoma. Most of the trials on checkpoint inhibitors and targeted therapy have not excluded patients with vulvar melanoma and the preliminary evidence is reviewed in the manuscript. Surgery remains the primary treatment modality of locally resectable vulvar cancer. In view of the rarity, the procedure should be performed in dedicated cancer centers to achieve optimal disease control and maintain continence and sexual function whenever possible. |
format | Online Article Text |
id | pubmed-6972795 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69727952020-01-27 Vulvar malignancies: an interdisciplinary perspective Wohlmuth, Christoph Wohlmuth‐Wieser, Iris J Dtsch Dermatol Ges CME‐Artikel Vulvar cancer represents the fourth most common gynecologic malignancy and is often encountered by the general Dermatologist or Gynecologist. Dermatooncologists and Gynecologic Oncologists share expertise in this field and the diagnosis and treatment should ideally be interdisciplinary. All subtypes are typically seen in the later decades of life, although all histologic subtypes have been described in women younger than 30 years. The diagnosis is often delayed. Exact mapping of biopsies is of high importance, as the location and distance from the midline guides the surgical approach depending on the underlying histology. Squamous cell carcinoma accounts for more than 76 % of vulvar cancer with vulvar intraepithelial neoplasia being an important precursor. Basal cell carcinoma is the second most common vulvar malignancy. Melanoma accounts for 5.7 % of vulvar cancer and has a worse prognosis compared to cutaneous melanoma. Most of the trials on checkpoint inhibitors and targeted therapy have not excluded patients with vulvar melanoma and the preliminary evidence is reviewed in the manuscript. Surgery remains the primary treatment modality of locally resectable vulvar cancer. In view of the rarity, the procedure should be performed in dedicated cancer centers to achieve optimal disease control and maintain continence and sexual function whenever possible. John Wiley and Sons Inc. 2019-12-12 2019-12 /pmc/articles/PMC6972795/ /pubmed/31829526 http://dx.doi.org/10.1111/ddg.13995 Text en © 2019 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | CME‐Artikel Wohlmuth, Christoph Wohlmuth‐Wieser, Iris Vulvar malignancies: an interdisciplinary perspective |
title | Vulvar malignancies: an interdisciplinary perspective |
title_full | Vulvar malignancies: an interdisciplinary perspective |
title_fullStr | Vulvar malignancies: an interdisciplinary perspective |
title_full_unstemmed | Vulvar malignancies: an interdisciplinary perspective |
title_short | Vulvar malignancies: an interdisciplinary perspective |
title_sort | vulvar malignancies: an interdisciplinary perspective |
topic | CME‐Artikel |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972795/ https://www.ncbi.nlm.nih.gov/pubmed/31829526 http://dx.doi.org/10.1111/ddg.13995 |
work_keys_str_mv | AT wohlmuthchristoph vulvarmalignanciesaninterdisciplinaryperspective AT wohlmuthwieseriris vulvarmalignanciesaninterdisciplinaryperspective |